By suppressing neuroinflammation, simufilam may also reduce insulin resistance associated with AD: neuroinflammation in both AD and obesity or type 2 diabetes induces insulin resistance and insulin receptor dysfunction [58,59]. The gene discussed is INSR; the disease is type 2 diabetes mellitus.